PILA PHARMA AB is a private, Swedish “micro-pharma” aiming at developing innovative new approaches to treat diabetes. PILA PHARMA owns issued use-patents that give the exclusive right to treat diabetes and obesity with antagonists of the TRPV1 receptor. The company has recently acquired the TRPV1 antagonist asset previously owned by Ario Pharma Ltd (Cambridge, U.K.).
This asset includes a series of small molecule TRPV1 antagonists including the clinical ready and safe development candidate XEN-D0501, patents, know-how and data.
The TRPV1 target (also called the “chili-receptor”) has been shown to have applications across pain and inflammatory diseases and is speculated to have a role in diabetes as well.
PILA PHARMA AB is dedicated to bringing the TRPV1 antagonist, a truly innovative oral anti-diabetes product closer to the market. And in addition to our current research collaborations, we intend to finance the development of our pre-clinical candidate through partnering, venture capital, corporate funds and/or grants.
The Nordic-American Life Science Conference.
December 1, 2016, New York, USA.
The Nordic-American Life Science Conference.eu
November 7–9, 2016, Cologne, Germany.
French-Swedish Life Science Day 2016.
October 20, 2016 at the Swedish Embassy, 17 Rue Barbet de Jouy, in Paris.
French-Swedish Life Science Day.eu
Nordic Life Science Days is the largest Nordic partnering conference for the global Life Science industry.
September 14-15, 2016, Stockholm, Sweden.
Nordic Life Science Days.com
Boehringer Partnering Day.
September 13, 2016, Stockholm, Sweden.
52nd EASD (European Association for the Study of Diabetes) Annual Meeting.
September 12-16, 2016, Munich, Germany.
Anglo-Nordic Lifescience Conference XIII
May 19, 2016 London, United Kingdom
Dansk Bioteks Årsmøde
May 4, 2016 Copenhagen, Denmark
Bio-Europe Spring 2016
April 4-6 2016, Stockholm, Sweden
10th Swiss-Scandinavian Bio-Business Seminar
February 10, 2016 at SIX Stock Exchange building in Zurich, Switzerland